Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Effects of 3 months of 2-g n-3 PUFA supplementation on clot properties, coagulation parameters and platelet function

From: Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes

Variable Placebo n-3 PUFAs p value
Fibrinogen (g/L)
 Before 2.70 (2.60; 2.95) 2.74 (2.60; 2.97) 0.70
 After 2.73 (2.58; 2.85) 2.72 (2.57; 2.87) 0.91
t50% (min)
 Before 13.14 (±2.77) 13.55 (±3.07) 0.55
 After 12.58 (±2.70) 13.76 (±2.59) 0.07
Lag time (min)
 Before 2.94 (2.52; 3.27) 2.61 (2.33; 3.21) 0.35
 After 2.94 (2.60; 3.28) 2.84 (2.56; 3.17) 0.75
Peak (nM)
 Before 264.54 (220.08; 314.92) 247.05 (211.89; 287.34) 0.27
 After 249.59 (190.94; 336.52) 243.83 (207.82; 293.65) 0.98
tt peak (min)
 Before 5.87 (±0.92) 5.94 (±1.03) 0.76
 After 5.62 (5.00; 6.96) 5.98 (4.96; 6.89) 0.89
F1.2 (pg/mL)
 Before 41.40 (28.80;48.10) 34.70 (26.95; 46.85) 0.56
 After 43.70 (33.90; 49.30)* 37.70 (27.40; 41.55)** 0.04
PR ADP (%)
 Before 57.96 (±14.02) 54.44 (±14.27) 0.36
 After 60.56 (±15.12) 58.19 (±12.52) 0.54
  1. Data shown as number (percentage) for categorical variables and mean (±standard deviation) or median (IQR) for continuous variables
  2. Ks permeation coefficient, t50% clot lysis time, Lag time lag time peak height, ETP endogenous thrombin potential (an area under the thrombin concentration versus the time curve), Peak maximal thrombin concentration, tt peak time do peak, F1.2 prothrombin fragments, PR ADP platelet aggregation 10 µmol/L adenosine diphosphate, PR AA platelet aggregation 5 mmol/L arachidonic acid
  3. * p = 0.05 within the placebo group; ** p = 0.53 within the n-3 PUFA group
Back to article page